The mood is better than the numbers suggest. The doom-loop panic of March and April is behind us, even though the XBI has ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall ...

HQH offers high yields with a biotech and small/mid-cap tilt, but relies on capital payouts, making it less tax efficient and ...

KKR & Co.-backed venture capital firm Catalio Capital Management gathered more than $400 million for its latest fund, a ...

"If a company isn't IPO-ready, it better be M&A-ready," says Nanna Luneborg of Forbion Capital Partners. She and co-founder Sander Slootweg sit down with Bloomberg Intelligence analyst Sam Fazeli to ...

A group of 53 biotech leaders are expressing their support for mifepristone in a letter to the Food and Drug Administration, ...

The NATO Innovation Fund has made its first investment in a biotechnology company, it said on Monday, seeking to enhance ...

Is the day of the zombie biotech coming to an end? Eyes have it: Peninsula biotech focuses on glaucoma, more in big test Eyes have it: Peninsula biotech focuses on glaucoma, more in big test © 2025 ...

As artificial intelligence continues to redefine industries, its most transformative impact in biotech is happening b ...

Top Create Biotech has filed for an initial public offering. The biotechnology company said Wednesday that it intends to list shares under the ticker symbol TCBG on the Nasdaq Capital Market. Top ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.